Emerging Treatment Options for Complicated Skin and Skin Structure Infections: Oritavancin

@inproceedings{Townsend2010EmergingTO,
  title={Emerging Treatment Options for Complicated Skin and Skin Structure Infections: Oritavancin},
  author={Mary Lee Townsend and Dustin Christopher Wilson and Melanie W. Pound and Richard H Drew},
  year={2010}
}
Oritavancin is a semisynthetic lipoglycopeptide with in vitro activity against a variety of aerobic Gram-positive pathogens (including drug-resistant forms of staphylococci, streptococci, and enterococci) and select anaerobic organisms. Available published clinical efficacy and safety studies in humans to date focus primarily in the treatment of complicated skin and skin structure infections. While oritavancin doses in these studies varied, single daily doses of 200 mg (300 mg in patients >100… CONTINUE READING

Citations

Publications citing this paper.

Oritavancin: an investigational lipoglycopeptide antibiotic.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2013
VIEW 2 EXCERPTS
CITES METHODS & BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

Efficacy of oritavancin at single or infrequent doses for the treatment of complicated skin and skin structure infections

LM Dunbar, J Milata, +3 authors MM Wasilewski
  • 2009

Hepatic Insufficiency and Outcomes in Patients with Complicated Skin and Skin Structure Infections Treated with Oritavancin

CS Hartman, MM Wasilewski, Moriarty, BM Bates
  • 2009

In vitro activity profile of oritavancin against resistant stapylococcal populations from a recent surveillance intiative

DF Sahm, G Moeck, FF Arhin, DC Draghi
  • 2009

Oritavancin kills S . aureus by increasing membrane permeability without causing extensive cell lysis : comparative studies with vancomycin , daptomycin , and lysostaphin

P Baudoux, HA Nguyen, +3 authors PM Tulkens
  • 2009

Pharmacokinetics and pharmacokineticspharmacodynamics of oritavancin against Staphylococcus aureus using data from a neutropenic murine thighinfection model

O Okusanya, D Lehoux, SA VanWart
  • 2009

Pharmacokinetics and pharmacokineticspharmacodynamics of oritavancin against Steptococcus pyogenes using data from a neutropenic murine thighinfection model

OO Okusanya, D Lehoux, SA VanWart
  • 2009